<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1626">
  <stage>Registered</stage>
  <submitdate>13/07/2007</submitdate>
  <approvaldate>13/07/2007</approvaldate>
  <nctid>NCT00501657</nctid>
  <trial_identification>
    <studytitle>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</studytitle>
    <scientifictitle>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>061025</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastroparesis</healthcondition>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sitagliptin
Treatment: drugs - Placebo

Experimental: Sitagliptin (100mg) - Active drug (sitagliptin)

Placebo Comparator: Placebo (sugar pill) - Inactive drug (placebo)


Treatment: drugs: Sitagliptin
100mg mane for 2 days

Treatment: drugs: Placebo
100mg mane for 2 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gastric emptying rate</outcome>
      <timepoint>4 hours per study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite</outcome>
      <timepoint>4 hours per study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female (females must be using an appropriate contraceptive method)

          -  18 - 45 years

          -  Body mass index (BMI) 19 - 25 kg/m2.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or
             significant gastrointestinal symptoms

          -  Subjects taking medication known to influence gastrointestinal function

          -  Alcohol intake &gt; 20 g per day

          -  Smoking &gt; 10 cigarettes per day

          -  Pregnant and/or lactating females

          -  Calculated creatinine clearance &lt; 60 ml/min

          -  Exposure to ionising radiation for research purposes in the previous 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Discipline of Medicine, Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate
      at which the stomach empties, and the release of gut hormones and blood glucose
      concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to
      reduce the blood glucose (sugar) response to a meal and this may potentially be due to
      slowing of stomach emptying. This is particularly relevant to people who have diabetes, in
      whom normalization of elevated blood glucose levels is important to maintain health.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00501657</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Karen L Jones, PhD</name>
      <address>University of Adelaide, Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>